Halozyme Therapeutics, Inc. · NASDAQ:HALO

Halozyme Therapeutics — Investor Presentation (January 2025)

19 slides from Halozyme Therapeutics's investor presentation, Jan 8, 2025

  1. Slide 1: Halozyme Therapeutics, Inc. Financial and Investor Update

    Halozyme Therapeutics, Inc. Financial and Investor Update NASDAQ: HALO January 2025 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements The financial results presented herein are preliminary, estimated, and unaudited. They are subject to the including, without limitation, statements conce

  3. Slide 3: Reiterating 2024 Raised Guidance and Raising 2025 Financial Guidance

    Reiterating 2024 Raised Guidance and Raising 2025 Financial Guidance Previous Raised Year-over-Year 2024 Estimate1,2 2025 Guidance 2025 Guidance Growth3 Total Revenue $970M - $1,020M $1,095 - $1,170M $1,150 - $1,225M 16 - 23% Royalty Revenue $550M - $565M $650 - $675M $725 - $750M 30 - 35% Adjusted

  4. Slide 4: Multiple Recent and Projected Product and Indication Launches Expected to Fuel ENHANZE Royalty Revenue Growth 2025 to 2028

    Multiple Recent and Projected Product and Indication Launches Expected to Fuel ENHANZE® Royalty Revenue Growth 2025 to 2028 2023 2024 2025 Nivolumab SC EU potential VYVGART Hytrulo approval in (PFS) 2025 U.S. potential approval April 2025 VYVGART Hytrulo Tecentriq (CIDP) Hybreza EU potential U.S. ap

  5. Slide 5: VYVGART & VYVGART Hytrulo SC Projected for Blockbuster Growth to ~$5B in 2028

    VYVGART® & VYVGART® Hytrulo SC Projected for Blockbuster Growth to ~$5B in 2028 Quarterly Net Sales for VYVGART & VYVGART Hytrulo20% ($M) Analyst Projections for VYVGART & VYVGART Hytrulo ($B)1 (ONLY gMG and CIDP) Quarter-over-Quarter Growth Year-over-Year Growth $573 20% $4.8 17% 20% $478 $4.1 6% 2

  6. Slide 6: Multiple Potential Drivers for Additional VYVGART Hytrulo SC Future Growth

    Multiple Potential Drivers for Additional VYVGART® Hytrulo SC Future Growth Studies evaluated VYVGART® & VYVGART® Hytrulo (IV & SC)1 Current studies evaluating VYVGART® Hytrulo (SC)1 Bullous Pemphigoid (BP) Thyroid Eye Disease (TED) Significant runway for Systemic Sclerosis growth with future Antibo

  7. Slide 7: DARZALEX SC with ENHANZE, With >90% U.S. Share of Sales, Driving Robust Long-Term Growth

    DARZALEX® SC with ENHANZE®, With >90% U.S. Share of Sales, Driving Robust Long-Term Growth Total DARZALEX® Sales IV+SC ($B) 1 Year-over-Year Growth 7% 9% $17.5 12% $16.3 15% $14.9 20% $13.3 21% $11.6 33% $9.7 43% $8.0 $6.0 $4.2 2020 2021 2022 2023 2024E 2025E 2026E 2027E 2028E U.S. annual exit SC sh

  8. Slide 8: PHESGO, With 100% Use SC with ENHANZE, On Trajectory to $3.4B Sales

    PHESGO®, With 100% Use SC with ENHANZE®, On Trajectory to $3.4B Sales PHESGO® Projected Sales ($B)1 Year-over-Year Growth 6% $3.4 10% $3.2 $2.9 16% $2.5 32% $1.9 58% $1.2 71% $0.7 133% $0.3 2021 2022 2023 2024E 2025E 2026E 2027E 2028E 1 Analysts’ consensus from Evaluate Ltd December 2024 8

  9. Slide 9: Robust Pipeline of Approved Near-Term Growth Catalysts Represent ~$25B Opportunity in 2028

    Robust Pipeline of Approved Near-Term Growth Catalysts Represent ~$25B Opportunity in 2028 10-minute subcutaneous injection ~7-minute subcutaneous injection ~3-5 minute subcutaenous injection vs. multiple hours IV infusion(administration vs. 30-60 minute IV infusion vs. 30 minute IV infusion and mon

  10. Slide 10: ENHANZE Royalties Key Revenue Driver Projecting $1B of Royalty Revenue in 2027

    ENHANZE® Royalties Key Revenue Driver Projecting $1B of Royalty Revenue in 2027 ~$20B Projected Sales ~$35B Projected Sales in 20281 In 20281 2013 - 2020 Launches 2023 - 2024 Launches 2 3 Projected Launches Amivantamab SC Licensees are responsible for development and commercialization 1 Analysts’ co

  11. Slide 11: Reiterating 2024 Raised Guidance and Raising 2025 Financial Guidance

    Reiterating 2024 Raised Guidance and Raising 2025 Financial Guidance Previous Raised Year-over-Year 2024 Estimate1,2 2025 Guidance 2025 Guidance Growth3 Total Revenue $970M - $1,020M $1,095 - $1,170M $1,150 - $1,225M 16 - 23% Royalty Revenue $550M - $565M $650 - $675M $725 - $750M 30 - 35% Adjusted

  12. Slide 12: Multi-Year Guidance Shows Projected Doubling of Key Guidance Metrics 2024-2028

    Multi-Year Guidance Shows Remarkable Projected Doubling of Key Guidance Metrics 2024-2028, Ten Years After First ENHANZE® Product Launch Total Revenue Royalty Revenue 2024 and 2028 2024 and 2028 $1,735 - $1,860 +81% +111% $1,150 - $1,200 $970 - $1,020 $550 - $565 2024E 2028E 2024E 2028E Adjusted EBI

  13. Slide 13: Strong Momentum in 2024 Resulting in Raised Total Revenue and Royalty Revenue Projections

    Strong Momentum in 2024 Resulting in Raised Total Revenue and Royalty Revenue Projections Total Revenue ($M) Total Royalties ($M) 2023-2028 2023-2028 CAGR CAGR +5% 17% +4% 21% +16% +22% 1,150-1,200 1,735-1,860 +25% 1,655-1,780 1,100-1,150 +25% 20% +19% 1,430-1,530 16% 900-940 +20% +32% 1,150-1,225 7

  14. Slide 14: Strong Momentum in 2024 Resulting in Raised Adjusted EBITDA and Non-GAAP EPS Projections

    Strong Momentum in 2024 Resulting in Raised Adjusted EBITDA and Non-GAAP EPS Projections Adjusted EBITDA ($M) Non-GAAP Diluted EPS ($ per share) 2023-2028 2023-2028 CAGR CAGR +6% 26% +23% +3% 25% +22% 1,275-1,400 8.25-8.85 1,205-1,330 8.00-8.60 +33% +31% 23% 25% 1,000-1,080 6.50-7.00 +28% +26% 755-8

  15. Slide 15: Strong Momentum in 2024 Resulting in Raised Multi-Year Projections

    Strong Momentum in 2024 Resulting in Raised Multi-Year Projections 2024 $M, except EPS (unaudited) 2023 Unaudited 2023-2028 2025 2026 2027 2028 Actual8 Preliminary CAGR7 Estimates8 Royalties1 447.9 550 – 565 725 – 750 900 – 940 1,100 – 1,150 1,150 – 1,200 21% Product Sales2 300.9 290 – 305 325 – 345

  16. Slide 16: Demonstrated Ability to Rapidly De-Lever Following M&A

    Demonstrated Ability to Rapidly De-Lever Following M&A Net Debt1 / LTM EBITDA 3.1x 2.7x ~1.4x 0.6x Close -1 Close 2 Close +1 Estimate3 (6/30/2021) (6/30/2022) (6/30/2023) (12/31/2024) $850M Cash Deployed to Share Repurchases4 LTM Revenue ($M) $412 $487 $774 $970 - $1,020 1 Net Debt calculated as con

  17. Slide 17: GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

    GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA (1) Amounts relates to a fair value gain on contingent liability due to the termination of the TLANDO license agreement in September 2023 (“TLANDO Termination”). (2) Amount relates to inventory write-off due to TLANDO Termination and amorti

  18. Slide 18: GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS

    Halozyme Therapeutics, Inc. GAAP to Non-GAAP Reconciliation Net Income and Diluted EPS $ in Thousands, except per share amounts Twelve Months Ended December 31, 2023 GAAP Net Income $ 281,594 Adjustments Share-based compensation 36,620 GAAP to Non-GAAP Amortization of debt discount Amortization of i

  19. Slide 19: GAAP to Non-GAAP Reconciliation: EBITDA, Adjusted EBITDA and Diluted EPS

    Halozyme Therapeutics, Inc. GAAP to Non-GAAP Reconciliation Preliminary Net Income and Diluted EPS Estimates (Unaudited) ($ in Millions, except per share amounts) GAAP to Non-GAAP Twelve Months Ended December 31, 2024 Reconciliation: GAAP Net Income $ 419 - $ 443 Adjustments Investment and other inc

Halozyme Therapeutics — Investor Presentation (January 2025) on 6ix